Emerging therapies for pericarditis: from anti-IL-1 agents to novel therapeutic options. (PubMed, Expert Opin Emerg Drugs) - Oct 1, 2026 - "We review key trials of IL-1 inhibitors, NLRP3 inhibitors (VTX2735), and other innovations (e.g. cannabidiol-based CardiolRx)...Randomized-withdrawal trials support a marked reduction in recurrences with IL-1 blockade in selected patients with inflammatory, colchicine-resistant and corticosteroid-dependent RP. However, open-label enrichment, small samples, short follow-up, uncertain durability after withdrawal, cost, and limited evidence outside idiopathic or post-cardiac injury disease restrict generalizability. New pipeline agents hold promise for broader use, however remain investigational until controlled trials establish their efficacy and long-term safety."
Journal • Review • Cardiovascular • Fatigue • Inflammation • Pain • NLRP3
|
|
Davide Stolfo; Francesco Venturelli; Giulio Savonitto; Maria Cristina Tomat; Massimo Imazio; Valentino Collini
|